ADD to BW1113 (MYLAN-LABORATORIES) Fourth Quarter and Fiscal Year Results Set All Time Company Record.

PITTSBURGH--(BUSINESS WIRE)--May 3, 1995--Add to BW1113: -0-

                Mylan Laboratories Inc. and Subsidiaries
                   Consolidated Statements of Earnings
                  For the Three Months and Years Ended
                         March 31, 1995 and 1994

                         Three Months Ended            Year Ended
                             March 31,                  March 31,
                           (Unaudited)                  (audited)
                      1995             1994         1995         1994

Net sales         $110,690,000      $69,074,000   $396,120,000 $251,773,000
Cost and expenses:
Cost of sales       49,670,000       35,003,000    169,590,000  125,631,000
Research and
 development         9,399,000        5,195,000     30,533,000   21,648,000
Selling and
 administrative     13,712,000       12,405,000     58,035,000   49,173,000
                    72,781,000       52,603,000    258,158,000  196,452,000

Equity in earnings
  of Somerset        5,587,000        5,346,000     25,406,000   23,596,000
Other income         2,945,000          667,000      7,958,000    8,148,000
Earnings before
 income taxes       46,441,000       22,484,000    171,326,000    87,065,000
Income tax rate             28%              23%            29%          16%
Income taxes        13,199,000        5,090,000     50,457,000    13,998,000
Net earnings       $33,242,000      $17,394,000   $120,869,000  $ 73,067,000
Earnings per share       $0.42            $0.22     $     1.52        $  .93
Weighted average common
 shares             79,409,000       79,169,000     79,309,000    78,949,000

    The company paid regular quarterly cash dividends of $.03 per
share from October 1992 to July 1993, 4 cents per share from October
1993 to July 1994 and 5 cents per share from October of 1994 to
April 1995.  In addition, the company paid a special one-time
dividend of 10 cents per share in January 1995.
    Mylan's 50% share of the net sales of Somerset for the three
months ended March 31, 1995 and 1994 was $12,636,000 and $11,931,000
respectively and for the year then ended was $62,988,000 and
$55,985,000 respectively.  Somerset's contribution to our net
earnings per share for the three month and one year periods was 6
cents and 28 cents in 1995 and 6 cents and 27 cents in 1994.
-0-

               Mylan Laboratories Inc. and Subsidiaries
                 Comparative Condensed Balance Sheets
                      March 31, 1995 and 1994
                             (Audited)

                                       1995          1994
                                         (In thousands)

Assets
 Current assets:
   Cash                             $ 127,280     $ 75,526
   Marketable securities               52,575       12,925
   Accounts receivable                 58,343       55,430
   Inventories                         78,205       57,996
   Deferred tax benefit - current      10,545        2,082
   Other current assets                 4,435        5,614

    Total current assets              331,383      209,573

Property, plant and equipment -
 at cost less accumulated
 depreciation                          92,299       82,514
Investments in and advances to
 Somerset                              22,055       17,763
Deferred tax benefit, non-current       1,043            0
Marketable securities, non-current     21,958       12,125
Intangible and other assets            77,463       81,350
               Total assets          $546,201     $403,325
Working capital                      $275,032     $191,647
Current ratio                        5.9 to 1    11.7 to 1

Liabilities and Shareholders' Equity
 Current liabilities:
   Cash dividend payable             $  3,976     $  3,171
   Accounts payable and other
    current liabilities                52,375       14,755
   Total current liabilities           56,351       17,926
Deferred taxe liability                     0          821
Long-term obligations                   7,122        4,609
Common stock and additional paid-in
 capital                               97,563       94,121
Unrealized gain on investment           1,374            0
Retained earnings                     386,212      288,357
                                      485,149      382,478

Less treasury stock                     2,421        2,509
  Net worth                           482,728      379,969
  Total liabilities & shareholders'
   equity                            $546,201     $403,325
Book value per share                 $   6.09     $   4.81

CONTACT: Mylan Labs, Pittsburgh

Patricia Sunseri, 412/232-0100